Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) EnantiomersIn Vitroand in the MPTP-Lesioned Primate:R-MDMA Reduces Severity of Dyskinesia, WhereasS-MDMA Extends Duration of ON-Time
Journal of Neuroscience May 11, 2011 Philippe Huot, Tom H. Johnston, Katie D. Lewis et al. 83 citations
l -3,4-Dihydroxyphenylalanine ( l -DOPA) is the most effective treatment for Parkinson's disease, but long-term l -DOPA administration is marred by the emergence of motor complications, namely, dyskinesia and a shortening of antiparkinsonian benefit (wearing-OFF). 3,4-Methylenedioxymethamphetamine (MDMA) is unique in that it exerts antidyskinetic effects and may enhance antiparkinsonian actions...